A high-level overview of Ligand Pharmaceuticals Incorporated (LGND) stock. View (LGND) real-time stock price, chart, news, analysis, analyst reviews and more.

A Look at Receptor–Ligand Pairs for Active-Targeting Drug Delivery from Crystallographic and Molecular Dynamics Perspectives. Gergana Gocheva. Gergana Gocheva. Sofia University “St. Kliment Ohridski”, ...

At Ligand Pharmaceuticals Inc (NASD: LGND), 3 different insiders purchased 855 shares at an average price of $43.79/share, for a total [...] By Dividend Channel Contributor Nov 22, 2013 ...

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025. JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ...

Among the antibodies tested (Eberhart et al., 2000; Holash and Pasquale, 1995; Soans et al., 1994, 1996), antibodies to the ephrin-A1 ligand and the EphA2 receptor most prominently labeled blood ...

Ligand L5 has Brønsted basicity very similar to that of L4, ... The Pd(II) complexes of the ambidentate pyridyldiketones 2,2-dimethyl-5-(3- or 4-pyridyl)pentane-3,5-dione are readily prepd. in their ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

LOS ANGELES, June 03, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO ...

A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).

Delta-like ligand 3 (DLL3), a Notch signaling regulator overexpressed in 70–80% of SCLC tumors, has emerged as a simultaneous biomarker and therapeutic target. This review aims to synthesize recent ...